Regeneron’s Oncology Strategy Gets Warmer With Early Prostate Data
Company Posts Solid Q2 Sales Despite REGEN-COV Drop
The costimulatory bispecific antibody REGN5678, meant to turn “cold” prostate cancer tumors “hot” and vulnerable to PD-1 inhibitors, showed early signs of efficacy combined with Libtayo.
